Multimodal Imaging to Assess Disease Activity and Predict Fluid Resolution in Patients with wAMD Treated with Brolucizumab: The IMAGINE Study.

Ophthalmol Ther · 2025 · PMC12413378 · PMID 40833455

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The HADS-A score significantly decreased from baseline to week 48, suggesting that anxiety was alleviated after treatment, while other parameters showed improvement but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.